Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 19/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25932190 | 0.88 | HDAC11 (0.59) | HDAC11HDAC8CHRM4CHRM5CHRM1 | |
| SCHEMBL21496707 | 0.87 | HDAC11 (0.71) | HDAC11HDAC8 | |
| SCHEMBL30038153 | 0.86 | HDAC11 (1.00) | HDAC11HDAC8 | |
| SCHEMBL21500610 | 0.86 | HDAC11 (1.00) | HDAC11HDAC8 | |
| SCHEMBL25932193 | 0.85 | HDAC11 (0.76) | HDAC11HDAC8 | |
| SCHEMBL21496797 | 0.83 | HDAC11 (0.74) | HDAC11HDAC8 | |
| SCHEMBL25932131 | 0.82 | HDAC11 (0.70) | HDAC11HDAC8 | |
| SCHEMBL21496775 | 0.80 | HDAC11 (0.69) | HDAC11HDAC8 | |
| SCHEMBL30040001 | 0.80 | HDAC11 (0.69) | HDAC11HDAC8 | |
| SCHEMBL30038142 | 0.79 | HDAC11 (0.73) | HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885CHRM4 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.